HLA‐matched allogeneic anti‐CD19 CAR‐T therapy in treating a relapsed/refractory acute lymphoblastic leukemia patient with high tumor burden
Abstract The genetically engineered chimeric antigen receptor T cell (CAR‐T) therapy has shown remarkable clinical efficacy in the treatment of hematological malignancies. Nonetheless, it is difficult to harvest adequate autologous T cells to manufacture potent CAR‐T cell products in patients with h...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-06-01
|
| Series: | ImmunoMedicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/imed.1032 |